아밀로이드증 치료 시장 규모, 점유율, 성장 분석 : 유형별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Amyloidosis Treatment Market size was valued at USD 6.32 Billion in 2024 and is poised to grow from USD 6.8 Billion in 2025 to USD 12.21 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The amyloidosis treatment market is experiencing notable expansion, driven by heightened awareness and improved diagnostic capabilities for this rare disease, where abnormal protein deposits lead to organ dysfunction. Key factors propelling market growth include advancements in therapeutic options, such as chemotherapy, stem cell transplants, and innovative targeted therapies like monoclonal antibodies and small molecule inhibitors that demonstrate potential in halting or reversing disease progression. Increased investment from pharmaceutical companies in research and development is fostering a competitive environment, with a focus on expanding treatment alternatives. However, challenges persist, particularly in terms of treatment affordability and the critical need for early diagnosis to enhance patient outcomes. Continued research efforts and the development of more effective therapies are poised to sustain this market's growth trend.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyloidosis Treatment Market Segments Analysis

Global Amyloidosis Treatment Market is segmented by Type, End-use and region. Based on Type, the market is segmented into Medication and Surgery. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyloidosis Treatment Market

A notable factor propelling the amyloidosis treatment market is the increasing incidence of the disease, which encompasses both AL amyloidosis and ATTR amyloidosis. With enhanced awareness and advancements in diagnostic techniques, a higher number of cases are being identified. This surge in diagnosis contributes to a growing patient population requiring effective treatment options. As the understanding of amyloidosis expands and more individuals are recognized as needing care, the market is positioned for significant growth, addressing the essential need for innovative therapies and comprehensive management solutions for those affected by this condition.

Restraints in the Amyloidosis Treatment Market

The amyloidosis treatment market faces significant challenges due to the limited availability of effective therapeutic options. Despite progress in research and drug development, current treatments do not yield satisfactory results for many patients affected by this condition. The existing therapies often fall short in their effectiveness, highlighting a critical need for the development of more innovative and efficient treatment solutions. Consequently, the quest for improved therapies remains a central concern within the market, as patients and healthcare providers seek better outcomes in managing this complex and challenging disease. This limitation underscores the urgency for continued research and advancement in the field.

Market Trends of the Amyloidosis Treatment Market

The amyloidosis treatment market is currently experiencing significant advancements driven by a strong focus on targeted therapies. Research and development in this sector are increasingly centered on innovative monoclonal antibodies and small molecules aimed at inhibiting the production or deposition of amyloid proteins, which are central to disease progression. With numerous clinical trials exploring the safety and efficacy of these promising novel therapies, there is a growing optimism regarding their potential to transform patient outcomes. This trend highlights a shift towards more personalized medicine strategies, enhancing treatment efficacy, and possibly leading to better management of this complex disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Amyloidosis Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Medication
  • Chemotherapy
  • Targeted therapy
  • Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
• Surgery
  • Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation

Global Amyloidosis Treatment Market Size by End-use & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Treatment Market Size & CAGR (2026-2033)

• North America (Type, End-use)
  • US
  • Canada
• Europe (Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proclara Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations